anonymous
Guest
anonymous
Guest
Tresiba is simply not good enough to justify price increments. Too similar to Glargine. Obviously Novo has major issues keeping up with insulin innovation. Looks much better in the GLP-1 arena (Lira, Sema). Over the coming years we will likely see Novo change from a 100% insulin company to a 50% insulin + 50 % GLP-1 company.